Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females between 18 and 65 years of age (inclusive).~2. Subjects who have given written consent.~3. Individuals in good health as per investigator judgement.~Exclusion Criteria:~1. If female, pregnancy or unwillingness to practice acceptable contraception.~2. If female, pregnant or breast-feeding or any positive/indeterminate pregnancy test.~3. Contraindication or precaution against Rabies and Japanese Encephalitis vaccination.~4. Unable to comprehend and to follow all required study procedures for the whole period of the study.~5. Participating in any other clinical trial 30 days prior to first study visit.~6. History of previous rabies/rabies immunoglobulin and/or Japanese Encephalitis immunization.~7. Receiving or planning to receive anti-malarial medications (e.g. Mefloquine) 14 days prior to Day 1 vaccination through Day 43.~8. Received any other vaccines within 2 weeks prior to enrollment in this study or plan to receive any vaccine within 4 weeks from the study vaccines.~9. Ever received blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 12 weeks.~10. Individuals who are part of study personnel or close family members conducting this study.~11. Body temperature ≥38 degrees Celsius (≥ 100.4° F) within 3 days of intended study vaccination.~12. Plans to travel within the next year to areas where Rabies and/or Japanese Encephalitis vaccine may be considered or offered. This includes but is not limited to India, Asia, Pacific-Rim, African countries.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- R/JE - Conv (Type: ACTIVE_COMPARATOR): Subjects received Rabies and Japanese Encephalitis (JE) vaccines following the conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm.
- R/JE - Acc (Type: EXPERIMENTAL): Subjects received Rabies and JE vaccines following the accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg; and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm.
- R - Conv (Type: ACTIVE_COMPARATOR): Subjects received Rabies vaccine following the conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and placebo on days 1, 8 and 29 in the left arm.
- JE - Conv (Type: ACTIVE_COMPARATOR): Subjects received JE vaccine following the conventional schedule, ie, placebo on days 1, 4, 8 and 29 in the right arm or leg; and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).